Citadel Advisors
ACRS icon

Citadel Advisors’s Aclaris Therapeutics ACRS Stock Holding History

Citadel Advisors’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.76M Buy
521,000
+54,600
+12% +$243K ﹤0.01% 5839
2026
Q1 		$1.75M Sell
466,400
-672,000
-59% -$2.27M ﹤0.01% 6376
2025
Q4 		$3.43M Buy
+1,138,400
New +$2.88M ﹤0.01% 4923
2025
Q2 		– Sell
-5,100
Closed -$7.8K – 12323
2025
Q1 		$7.8K Sell
5,100
-15,900
-76% -$33.9K ﹤0.01% 13673
2024
Q4 		$52.1K Buy
21,000
+17,500
+500% +$43.5K ﹤0.01% 12355
2024
Q3 		$4.03K Sell
3,500
-9,700
-73% -$11.9K ﹤0.01% 13599
2024
Q2 		$14.5K Sell
13,200
-24,300
-65% -$28.6K ﹤0.01% 12879
2024
Q1 		$46.5K Buy
37,500
+20,200
+117% +$24.1K ﹤0.01% 12234
2023
Q4 		$18.2K Sell
17,300
-208,000
-92% -$635K ﹤0.01% 12700
2023
Q3 		$1.54M Buy
225,300
+117,500
+109% +$1M ﹤0.01% 5706
2023
Q2 		$1.12M Sell
107,800
-9,500
-8% -$86K ﹤0.01% 6231
2023
Q1 		$949K Buy
117,300
+109,000
+1,313% +$1.38M ﹤0.01% 6888
2022
Q4 		$131K Buy
+8,300
New +$134K ﹤0.01% 10821
2022
Q1 		– Sell
-20,700
Closed -$301K – 13460
2021
Q4 		$301K Sell
20,700
-700
-3% -$10.6K ﹤0.01% 10912
2021
Q3 		$385K Sell
21,400
-21,400
-50% -$343K ﹤0.01% 10504
2021
Q2 		$752K Sell
42,800
-18,700
-30% -$425K ﹤0.01% 9094
2021
Q1 		$1.55M Sell
61,500
-7,300
-11% -$143K ﹤0.01% 7020
2020
Q4 		$445K Buy
68,800
+54,500
+381% +$230K ﹤0.01% 8365
2020
Q3 		$37K Buy
+14,300
New +$32K ﹤0.01% 9696

Other funds holding ACRS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Citadel Advisors's ACRS Position: Q2 2026 in Review

Citadel Advisors reduced its Aclaris Therapeutics (ACRS) stake by 22% in Q2 2026, selling an estimated $2.17M and leaving 1,762,081 shares worth $9.32M. The position accounts for ﹤0.01% of the portfolio, ranked #3676.

Citadel Advisors first reported a position in ACRS in Q3 2016 and has held it in 38 quarters since. The position peaked at $33.4M in Q1 2021. 149 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • Citadel Advisors held 1,762,081 shares of Aclaris Therapeutics worth $9.32M as of Q2 2026.
  • Citadel Advisors sold 487,238 Aclaris Therapeutics shares in Q2 2026, an estimated $2.17M.
  • Aclaris Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #3676 holding.
  • Citadel Advisors first reported a position in Aclaris Therapeutics in Q3 2016 and has held it in 38 quarters since.
  • Citadel Advisors's Aclaris Therapeutics position peaked at $33.4M in Q1 2021.
  • 149 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.